MSB 3.19% 97.0¢ mesoblast limited

Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-842

  1. 340 Posts.
    lightbulb Created with Sketch. 60
    As much as I have enjoyed the scientific speculation of e.g. tfn 4003 as a marker of efficacy... do apologies but feel at this moment in time to say 'bollocks" to the many posters who, I think have a somewhat delusional inflated idea about their qualification to make scientific speculations in terms of this company. .Interested to see the next 6 months though
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.